venipunctures
PreclinicalBiologic
venipunctures is one of 10 biologic programs targeting Psychiatric Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Psychiatric Disorder
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Lexapro
AbbVieApproved
Chantix
PPrism Pharmaceuticals
Approved
Pitocin
RRetrophin
Approved
Suboxone
IIndivior Inc.
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Dayvigo
EisaiPreclinical
Skyclarys
BiogenPreclinical
Conservative Treatment
PPeking University Third Hospital
Preclinical
venipunctures
CCentre Hospitalier Universitaire Dijon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psychiatric Disorder1 trial
A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders
Terminated·—·N/A·NCT03745235·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for venipunctures. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details